Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years?

Chest

Volumn 138, Issue 6, 2010, Pages 1464-1474

  Connors, Geoffrey R ^a   Christopher Stine, Lisa ^a   Oddis, Chester V ^b   Danoff, Sonye K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ANAPHYLAXIS; ASEPTIC MENINGITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; DERMATOMYOSITIS; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC INFLAMMATORY MYOPATHY; INFECTION; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; MYOPATHY; NEPHROTOXICITY; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; WEAKNESS;

EID: 78649951827     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-0180     Document Type: Review

References (125)

1. Ahlström G, Gunnarsson LG, Leissner P, Sjödén PO. Epidemiology of neuromuscular diseases, including the postpolio sequelae, in a Swedish county. Neuroepidemiology. 1993;12(5):262-269.
2. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al; Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J. 2003;22(2):245-250.
3. Frazier AR, Miller RD. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest. 1974;65(4):403-407.
4. Schwarz MI, Matthay RA, Sahn SA, Stanford RE, Marmorstein BL, Scheinhorn DJ. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine (Baltimore). 1976;55(1):89-104.
5. American Thoracic Society;European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277-304.
6. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967-972.
7. Golden A, Bronk TT. Diffuse interstitial fibrosis of lungs; a form of diffuse interstitial angiosis and reticulosis of the lungs. AMA Arch Intern Med. 1953;92(5):106-114.
8. Liebow AA, Carrington CB. The Interstitial Pneumonias. 1st ed. New York, NY : Grune and Stratton; 1969.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.
10. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
11. Tani K, Tomioka R, Sato K, et al. Comparison of clinical course of polymyositis and dermatomyositis: a follow-up study in Tokushima University Hospital. J Med Invest. 2007;54(3-4):295-302.
12. Ye S, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26(10):1647-1654.
13. Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297-301. (Pubitemid 38250674)
14. Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford). 2005;44(10):1282-1286.
15. Chen YJ, Wu CY, Shen JL. Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol. 2007;87(1):33-38.
16. Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007;101(8):1761-1769.
17. Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol. 2009 ;28(6):639-646.
18. Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614-622.
19. Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus. 2005;14(7):534-542.
20. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213-2217.
21. Porkodi R, Shanmuganandan K, Parthiban M, Madhavan R, Rajendran P. Clinical spectrum of inflammatory myositis in South India - a ten year study. J Assoc Physicians India. 2002;50:1255-1258.
22. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4(5):443-448.
23. Sakamoto N, Mukae H, Fujii T, et al. Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis. Intern Med. 2004;43(9):838-842.
24. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986;29(11):1365-1370.
25. Dalakas MC, Pezeshkpour GH, Gravell M, Sever JL. Polymyositis associated with AIDS retrovirus. JAMA. 1986;256(17):2381-2383.
26. Morgan OS, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet. 1989;2(8673):1184-1187.
27. Travers RL, Hughes GR, Cambridge G, Sewell JR. Coxsackie B neutralisation titres in polymyositis/dermatomyositis. Lancet. 1977;1(8024):1268.
28. Pearson CM. Editorial: Myopathy with viral-like structures. N Engl J Med. 1975;292(12):641.
29. Mikol J, Felten-Papaiconomou A, Ferchal F, et al. Inclusionbody myositis: clinicopathological studies and isolation of an adenovirus type 2 from muscle biopsy specimen. Ann Neurol. 1982;11(6):576-581.
30. Nishino H, Engel AG, Rima BK. Inclusion body myositis: the mumps virus hypothesis. Ann Neurol. 1989;25(3):260-264. (Pubitemid 19085517)
31. Rosenburg N. Experimental models of inflammatory myopathies. Baillieres Clin Neurol. 1993 ;2(3):693-715.
32. Nishikai M, Miyairi M, Kosaka S. Dermatomyositis following infection with hepatitis C virus. J Rheumatol. 1994;21(8):1584-1585.
33. Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum. 1998;28(2):107-113.
34. Agha B, Rasheed M, Kenyon L, Jimenez SA. Hepatitis C virus infection, inflammatory myopathy, and pulmonary fibrosis: are they related? J Clin Rheumatol. 2002;8(1):44-49.
35. Ueno Y, Kondo K, Kidokoro N, Kobashi R, Kanaji K, Matsumura T. Hepatitis C infection and polymyositis. Lancet. 1995;346(8970):319-320.
36. Weidensaul D, Imam T, Holyst MM, King PD, McMurray RW. Polymyositis, pulmonary fibrosis, and hepatitis C. Arthritis Rheum. 1995;38(3):437-439.
37. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119(12):1198-1208.
38. Ka?ifoǧlu T, Korkmaz C, Ozkan R. Cytomegalovirus-induced interstitial pneumonitis in a patient with dermatomyositis. Clin Rheumatol. 2006;25(5):731-733.
39. Magro CM, Crowson AN, Dawood M, Nuovo GJ. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J Rheumatol. 2002;29(6):1227-1235.
40. Magro CM, Wusirika R, Frambach GE, Nuovo GJ, Ferri C, Ross P Jr. Autoimmune-like pulmonary disease in association with parvovirus B19: a clinical, morphologic, and molecular study of 12 cases. Appl Immunohistochem Mol Morphol. 2006;14(2):208-216.
41. Magro CM, Allen J, Pope-Harman A, et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol. 2003;119(4):556-567.
42. Cherin P, Herson S, Crevon MC, et al. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. J Rheumatol. 1996;23(7):1135-1142. (Pubitemid 26240576)
43. Benveniste O, Chérin P, Maisonobe T, et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol. 2001;167(6):3521-3529.
44. Chino Y, Murata H, Goto D, et al. T cell receptor BV gene repertoire of lymphocytes in bronchoalveolar lavage fluid of polymyositis/dermatomyositis patients with interstitial pneumonitis. Int J Mol Med. 2006;17(1):101-109.
45. Berman JS, Beer DJ, Theodore AC, Kornfeld H, Bernardo J, Center DM. Lymphocyte recruitment to the lung. Am Rev Respir Dis. 1990;142(1):238-257.
46. Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease. A review of the pulmonary histopathologic findings. Arch Intern Med. 1981;141(8):1005-1010.
47. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990;141(3):727-733.
48. Yamadori I, Fujita J, Kajitani H, et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/ dermatomyositis. Rheumatol Int. 2001;21(3):89-93.
49. Kurasawa K, Nawata Y, Takabayashi K, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol. 2002;129(3):541-548.
50. Arnett FC, Hirsch TJ, Bias WB, Nishikai M, Reichlin M. The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol. 1981;8(6):925-930.
51. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360-374.
52. Furuya T, Hakoda M, Tsuchiya N, et al. Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. J Rheumatol. 2004;31(9):1768-1774.
53. Chinoy H, Salway F, Fertig N, et al; UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006;8(1):R13.
54. Vázquez-Abad D, Rothfield NF. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum. 1996;39(2):292-296.
55. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26(5):604-611.
56. Imbert-Masseau A, Hamidou M, Agard C, Grolleau JY, Chérin P. Antisynthetase syndrome. Joint Bone Spine. 2003;70(3):161-168.
57. Wasicek CA, Reichlin M, Montes M, Raghu G. Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype. Am J Med. 1984;76(3):538-544.
58. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77(282):1019-1038.
59. Ghirardello A, Zampieri S, Tarricone E, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006;39(3):217-221.
60. Grau JM, Miró O, Pedrol E, et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol. 1996;23(11):1921-1926.
61. Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60(7):2183-2192.
62. Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34(5):1012-1018.
63. Lega JC, Cottin V, Fabien N, Thivolet-Béjui F, Cordier JF. Interstitial lung disease associated with anti-PM/Scl or antiaminoacyl- tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37(5):1000-1009.
64. Katsumata Y, Ridgway WM, Oriss T, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29(2-3):174-186.
65. Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A. 1990;87(24):9933-9937.
66. Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125-3131.
67. Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196(6):781-791.
68. Levine SM, Rosen A, Casciola-Rosen LA. Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2003;15(6):708-713.
69. Wakasugi K, Schimmel P. Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J Biol Chem. 1999;274(33):23155-23159.
70. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science. 1999;284(5411):147-151.
71. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep. 2003;5(6):425-430.
72. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008;10(4):333-340.
73. Miller MR, Crapo R, Hankinson J, et al; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005;26(1):153-161.
74. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
75. Bonnefoy O, Ferretti G, Calaque O, et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol. 2004;49(3):235-244.
76. Hayashi S, Tanaka M, Kobayashi H, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol. 2008;35(2):260-269.
77. Shi JH, Xu WB, Liu HR, et al. Clinico-pathological manifestations in interstitial lung diseases associated with polymyositis-dermatomyositis [in Chinese ]. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31(4):250-254.
78. Ikezoe J, Johkoh T, Kohno N, Takeuchi N, Ichikado K, Nakamura H. High-resolution CT findings of lung disease in patients with polymyositis and dermatomyositis. J Thorac Imaging. 1996;11(4):250-259.
79. Mino M, Noma S, Taguchi Y, Tomii K, Kohri Y, Oida K. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol. 1997;169(1):83-87.
80. Mochimaru H, Kawamoto M, Enomoto T, et al. Transbronchial biopsy is clinically useful in classifying patients with interstitial pneumonia associated with polymyositis and dermatomyositis. Respirology. 2008;13(6):863-870.
81. Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol. 2005;32(1):58-64.
82. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44(6):585-596.
83. Wang PZ, Guan JL, Han XH. The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31(6):417-420.
84. Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/ dermatomyositis. Ann Rheum Dis. 2000;59(4):257-262.
85. Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39(6):632-636.
86. Kumánovics G, Minier T, Radics J, Pálinkás L, Berki T, Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol. 2008;26(3):414-420.
87. Krystufkova O, Vallerskog T, Helmers SB, et al. Increased serum levels of B-cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009 ;68(6):836-843.
88. Wong RC, Brown S, Clarke BE, Klingberg S, Zimmerman PV. Transient elevation of the tumor markers CA 15-3 and CASA as markers of interstitial lung disease rather than underlying malignancy in dermatomyositis sine myositis. J Clin Rheumatol. 2002;8(4):204-207.
89. Okada M, Suzuki K, Nakanishi T, Nakashima M. Serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases. Respirology. 2006;11(4):509-510.
90. Jankowska M, Butto B, Debska-Slizie A, Rutkowski B. Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome. Rheumatol Int. 2007;27(8):775-780.
91. Sakamoto S, Homma S, Kawabat M, Kono T, Motoi N, Yoshimur K. A case of corticosteroid-resistant nonspecific interstitial pneumonia associated with dermatomyositis successfully treated with cyclosporin A [in Japanese ]. Nihon Kokyuki Gakkai Zasshi. 2005;43(3):171-178.
92. Shimojima Y, Ishii W, Kato T, et al. Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern Med. 2003;42(12):1253-1258.
93. Ando S, Kobayashi S, Yamanaka K, Takasaki Y, Hashimoto H. Successful combination therapy of cyclosporine and steroids in two cases with interstitial pneumonitis associated with polymyositis [in Japanese ]. Ryumachi. 1995;35(1):95-99.
94. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38(5):383-392.
95. Guglielmi S, Merz TM, Gugger M, Suter C, Nicod LP. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J. 2008;31(1):213-217.
96. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114(2):154-163.
97. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762-1763.
98. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439-2446.
99. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30-36.
100. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009 ;337(5):329-335.
101. Lange U, Piegsa M, Müller-Ladner U, Strunk J. Anti-Jo-1 antibody positive polymyositis - successful therapy with leflunomide. Autoimmunity. 2006;39(3):261-264.
102. Murota H, Muroi E, Yamaoka T, Hamasaki Y, Katayama I. Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis. Allergol Int. 2006;55(2):199-202.
103. Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/ dermatomyositis. Lung. 2009;187(3):201-206.
104. Oryoji K, Himeji D, Nagafuji K, et al. Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol. 2005;24(6):637-640.
105. Songcharoen S, Raju SF, Pennebaker JB. Interstitial lung disease in polymyositis and dermatomyositis. J Rheumatol. 1980;7(3):353-360.
106. Takizawa H, Shiga J, Moroi Y, Miyachi S, Nishiwaki M, Miyamoto T. Interstitial lung disease in dermatomyositis: clinicopathological study. J Rheumatol. 1987;14(1):102-107.
107. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum. 1988;18(1):29-37.
108. Saeki T, Suzuki E, Watanabe T, et al. Prognosis of interstitial pneumonitis (IP) in polymyositis (PM)/dermatomyositis (DM) [in Japanese ]. Ryumachi. 1994;34(1):16-21.
109. Oddis CV. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12(6):492-497.
110. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182-1185.
111. Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol. 2003;32(3):181-183.
112. Malaviya AN, Many A, Schwartz RS. Treatment of dermatomyositis with methotrexate. Lancet. 1968;2(7566):485-488.
113. Sokoloff MC, Goldberg LS, Pearson CM. Treatment of corticosteroid- resistant polymyositis with methotrexate. Lancet. 1971;1(7688):14-16.
114. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4(4):723-730.
115. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):423-426.
116. Carroll GJ, Thomas R, Phatouros CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol. 1994;21(1):51-54.
117. Alarcón GS, Kremer JM, Macaluso M, et al; Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Ann Intern Med. 1997;127(5):356-364.
118. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987;14(6):1164-1171.
119. Turk JL, Parker D, Cameron AE. The effect of cyclophosphamide on immunological control mechanisms. Int J Tissue React. 1984;6(3):205-211.
120. Kotani T, Makino S, Kawasaki Y, et al. A case of interstitial pneumonia associated with dermatomyositis effectively treated with cyclosporin-A and cyclophosphamide pulse [in Japanese ]. Nihon Rinsho Meneki Gakkai Kaishi. 2005;28(3):148-153.
121. Shinohara T, Hidaka T, Matsuki Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med. 1997;36(7):519-523.
122. Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000;39(5):428-430.
123. Yoshida T, Koga H, Saitoh F, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med. 1999;38(9):733-738.
124. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124-130.
125. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719-1726.